Aurora Therapeutics has discontinued its lead gene-editing program targeting phenylketonuria. This decision stems from increasing competition within the field. The company also confirmed that "several" employees have been let go as a result of this strategic pivot. Aurora remains committed to developing gene editing solutions for rare diseases. They plan to focus on novel technologies addressing significant unmet medical needs.
San Francisco, California
https://www.biospace.com/business/bespoke-gene-editing-outfit-abandons-lead-program-cuts-several-employees